SAN FRANCISCO, July 29, 2025 (GLOBE NEWSWIRE) -- Girard Sharp LLP, a national investment, securities, and consumer class action firm, is investigating potential securities claims on behalf of former or current investors of 3M Company (“3M”) who received shares of Neogen Corporation (“Neogen” or the “Company”) in connection with Neogen’s acquisition of 3M’s Food Safety Business on September 1, 2022 (“Merger”).
Neogen is a Michigan corporation that, with its subsidiaries, “manufacture and market a diverse line of products and services dedicated to food and animal safety.” The Company’s Food Safety segment consists primarily of “diagnostic test products and complementary products (e.g., culture media) sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues and general sanitation concerns.” The Company’s Animal Safety segment is engaged in the “development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, diagnostic products, rodenticides, cleaners, disinfectants, insecticides and genomics testing services for the worldwide animal safety market.”
The offering materials for the Merger (“Offering Materials”) stated that the combined Company expected to “have improved EBITDA margins and stronger free cash flow relative to Neogen on a standalone basis, allowing Neogen to deleverage following the [Merger]” and “generate run-rate revenue and cost synergies of $30 million within three years following the closing of the [Merger] due to efficiencies in product innovation, sales, marketing, distribution and production.”
On January 10, 2025, Neogen announced its preliminary 2Q25 financial results and reported a net loss of $456.3 million due to a non-cash goodwill impairment related to the 3M Food Safety Division acquisition. Moreover, Neogen reported that, as of November 30, 2024, the Company had material weaknesses in its internal control over financial reporting. On April 9, 2025, Neogen announced its 3Q25 financial results, reporting a net loss of $11 million and a drop in revenue of 3.4% to $221 million. The Company also reported that its capital expenditures were expected to be approximately $100 million as a result of “lowered Adjusted EBITDA” and a “pull-forward of integration capex into fiscal 2025.” It also reported the Company’s CEO, John Adent, would be stepping down.
Since September 1, 2022, the date upon which Neogen issued shares to former or current 3M investors, Neogen’s share price has declined by 75%. Girard Sharp’s investigation focuses on whether the Offering Materials may have included misrepresentations and omissions regarding Neogen’s and 3M’s financial conditions and the Merger.
If you are a former or current 3M investor with losses, please fill out this form https://girardsharp.com/results-investigations/neogen-corporation-nasdaq-neog-securities-investigation/, email apolk@girardsharp.com, or call (866) 981-4800 for a free consultation.
Why Girard Sharp?
Girard Sharp represents investors, consumers, and institutions in class actions and other complex litigation nationwide. We recently obtained a $36.5 million securities settlement against Maxar Technologies, a space imagery company, after its share price collapsed following its acquisition of DigitalGlobe. Our attorneys have obtained multimillion-dollar recoveries for victims of unfair and deceptive practices in antitrust, financial fraud, and consumer protection matters against some of the country’s largest corporations, including Raymond James, John Hancock, and Sears. Girard Sharp has earned top-tier rankings from U.S. News and World Report for Securities and Class Action Litigation and has been repeatedly selected as an Elite Trial Lawyers finalist by the National Law Journal.
Contact
Girard Sharp LLP
(866) 981-4800
